Halozyme Therapeutics vs Bio-Techne

Halozyme Therapeutics (HALO), health care, and Bio-Techne (TECH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bio-Techne is worth $11.4B on the stock market and Halozyme Therapeutics $10.9B: Bio-Techne is valued at 4% more. Halozyme Therapeutics trades at 24.0 times earnings and Bio-Techne at 66.6; operating margins in their latest fiscal years were 33.6% and 20.7%. Over the past year Halozyme Therapeutics's share price has moved +37.7% and Bio-Techne's +25.2%.

Key facts

Halozyme Therapeutics market value
$10.9B
Bio-Techne market value
$11.4B
Halozyme Therapeutics P/E
24.0
Bio-Techne P/E
66.6
Halozyme Therapeutics revenue
$1.4BFY to 2025-12-31
Bio-Techne revenue
$1.2BFY to 2026-06-30
Superinvestors holding both
0

Market values as of .

Halozyme Therapeutics vs Bio-Techne: every measure side by side
Measure Halozyme Therapeutics Bio-Techne
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312026-06-30
Size
Market cap$10.9Blower$11.4Bhigher
Revenue$1.4Bhigher$1.2Blower
Earnings$316.9Mhigher$181.9Mlower
Employees423lower3,000higher
Total assets$2.5Blower$2.6Bhigher
Valuation
P/E24.0lower66.6higher
P/S7.8lower9.4higher
P/B—5.3
Dividend yield0.00%lower0.33%higher
Profitability
Operating margin33.6%higher20.7%lower
Balance sheet
Net assets$48.8Mlower$2.1Bhigher
Total liabilities$2.5Bhigher$478.5Mlower
Total debt$2.1Bhigher$200Mlower
Cash on hand$133.8Mlower$264.7Mhigher
Price change
Today-0.55%lower-0.22%higher
1 year+37.7%higher+25.2%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns HALO · Who owns TECH

Further comparisons

Learn

Questions and answers

Which is bigger, Halozyme Therapeutics or Bio-Techne?

By market value, Bio-Techne is the larger: $11.4B against $10.9B for Halozyme Therapeutics. By revenue in its latest fiscal year, Halozyme Therapeutics is the larger: $1.4B against $1.2B for Bio-Techne.

Which has the higher P/E ratio?

Bio-Techne: 66.6, against 24.0 for Halozyme Therapeutics. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Halozyme Therapeutics: 33.6%, against 20.7% for Bio-Techne. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Bio-Techne: 0.33%, against 0.00% for Halozyme Therapeutics. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Halozyme Therapeutics: $2.1B, against $200M for Bio-Techne. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Halozyme Therapeutics and Bio-Techne?

None of the tracked superinvestors holds both in their latest 13F filing. 5 hold Halozyme Therapeutics and 7 hold Bio-Techne.

Cite this page

Funkfolio, “Halozyme Therapeutics vs Bio-Techne”, data as of 17 November 2026. https://funkfolio.com/compare/halo-vs-tech

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.